JWH-202
JWH-202 is a synthetic cannabinoid that acts as a potent agonist at the cannabinoid receptors. It is part of the JWH series of compounds, which were developed by Dr. John W. Huffman in the 1990s for research into the endocannabinoid system.
Chemical Structure and Properties[edit | edit source]
JWH-202 is chemically classified as a naphthoylindole, a class of synthetic cannabinoids. Its chemical structure consists of a 1-pentyl-3-(2-methylphenylacetyl)indole core. The presence of the 2-methylphenyl group distinguishes it from other compounds in the JWH series.
Pharmacology[edit | edit source]
JWH-202 acts as a full agonist at both the CB1 and CB2 cannabinoid receptors, with a higher affinity for the CB1 receptor. This receptor is primarily found in the central nervous system, and its activation is associated with the psychoactive effects of cannabinoids. The CB2 receptor is more prevalent in the immune system.
Effects[edit | edit source]
The effects of JWH-202 are similar to those of tetrahydrocannabinol (THC), the primary psychoactive component of cannabis. Users may experience euphoria, altered perception, and relaxation. However, synthetic cannabinoids like JWH-202 can also lead to adverse effects such as anxiety, paranoia, and tachycardia.
Legal Status[edit | edit source]
The legal status of JWH-202 varies by country. In many jurisdictions, it is classified as a controlled substance due to its potential for abuse and lack of medical use. It is often included in legislation targeting synthetic cannabinoids.
Research and Applications[edit | edit source]
JWH-202, like other synthetic cannabinoids, has been used in scientific research to study the endocannabinoid system and the effects of cannabinoid receptor activation. However, due to its potential for abuse, its use is restricted in many areas.
Safety and Toxicology[edit | edit source]
The safety profile of JWH-202 is not well-established, and its use is associated with significant risks. Synthetic cannabinoids have been linked to severe health effects, including acute kidney injury, seizures, and psychosis.
Also see[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
